ClinicalTrials.Veeva

Menu
A

Advance Medical Research Center | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

GED-0301
Empagliflozin
M5049
695501
TRx0237
ITI-1284
Lorecivivint
Piromelatine
AVP-786
Diltiazem Hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 21 total trials

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-1)

The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active...

Enrolling
Cutaneous Lupus Erythematosus (CLE)
Systemic Lupus Erythematosus (SLE)
Drug: Standard of care (SoC)
Drug: Placebo

This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in pat...

Enrolling
Agitation Associated With Alzheimer's Dementia
Drug: Placebo
Drug: ITI-1284

This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).The study dur...

Active, not recruiting
Myositis
Dermatomyositis
Other: Placebo IV
Biological: Empasiprubart IV

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting
Alzheimer's Disease
Drug: Piromelatine 20 mg
Drug: Placebo

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting
Lower Respiratory Tract Illness
Biological: RSVpreF
Biological: Placebo

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Active, not recruiting
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: M5049 medium dose
Drug: M5049 high dose

Trial sponsors

Boehringer Ingelheim logo
Celgene logo
Merck KGaA (EMD Serono) logo
Pfizer logo
P
B
Bristol-Myers Squibb (BMS) logo
Intra-Cellular Therapies logo
Merck KGaA (EMD Serono) logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems